Gene therapeutic strategies for neurodegenerative diseases

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 5, 2000, Pages 540-554

  Baekelandt, V ^a   De Strooper, B ^a   Nuttin, B ^a   Debyser, Z ^a  

^a Laboratory of Experimental Neurosurgery and Neuroanatomy   (Belgium)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Gene therapy; Neurodegeneration; Parkinson's disease; Stereotactic neurosurgery; Vector

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; EXPRESSION VECTOR; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; HUMAN; PARKINSON DISEASE; REVIEW;

ADENOVIRIDAE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; RETROVIRIDAE; SIMPLEXVIRUS;

EID: 0033744695     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. The TMC worldwide gene therapy enrollment report, end 1996
2. Toward autologous ex vivo gene therapy for the central nervous system with human adult astrocytes
3. New prospects for human stem-cell therapy in the nervous system
4. Differentiation of adult hippocampus-derived progenitors into olfactory neurons in vivo
5. Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo
6. Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses
7. Bipotent progenitor cell lines from the human CNS
8. Embryonic stem cell lines derived from human blastocysts
9. Delivery of recombinant gene products to the central nervous system with non-autologous cells in alginate microcapsules
10. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
11. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF
12. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus
13. Neuronal progenitors-learning from the hippocampus
14. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus
15. Dopaminergic neurons protected from degeneration by GDNF gene therapy
16. Interleukin-1 medlates a rapid inflammatory response after injection of adenoviral vectors into the brain
17. Persistent transgene expression in the hypothalamus following stereotaxic delivery of a recombinant adenovirus: Suppression of the immune response with cyclosporin
18. Adenoviral vector-mediated gene expression in the nervous system of Immunocompetent Wistar and T cell-deficient nude rats: Preferential survival of transduced astroglial cells In nude rats
19. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy. Implications for clinical trials
20. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression end decreased toxicity
21. Adanovirus-mediated regulable target gene expression in vivo
22. Site-specific integration mediated by s hybrid adenovirus/adeno-associated virus vector
23. Recombinant adenoassociated virus type 2,4 and 5 vectors: Trsnsduction of variant cell types regions in the mammalian central nervous system
24. Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression
25. Differential end persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector
26. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters
27. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-essociatad virus vectors
28. Highly efficient and sustained gene transfer in adult neurons with s lentivirus vector
29. Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice
30. Increased motoneuron survival improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2
31. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer
32. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigrsl transduction promotes functional regeneration in the lesioned nigrostriatal system
33. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-Lamino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease
34. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors
35. Widespread integration and survival of adult-derived neural progenitor cells in the developing optic retina
36. In vivo gene delivery and stable transduction of non-dividing cells by s lentiviral vector
37. SteMs and efficient gene transfer into the retina using an HIV-based lentiviral vector
38. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
39. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
40. A third-generation lentivirus vector with a conditional packaging system
41. Self-inactivating lentivirus vector for safe end efficient in vivo gene delivery
42. Efficient transduction of non-dividing human cells by feline immunodeficiency virus lentiviral vectors
43. Sable gene transfer to the nervous system using a non-primate lentiviral vector
44. Lentivirus vectors using human simian immunodeficiency virus elements
45. Lentiviral vectors - The promise of gene therapy within reach?
46. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1
47. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into non-dividing cells
48. Infection of human fetal cardiac myocytes by a human immunodeficiency virus-1-derived vector
49. A stable system for the high-titer production of multiply attenuated lentiviral vectors
50. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system In Parkinson's disease
51. Gene transfer by lentiviral vectors is limited by nuclear translocation rescued by HIV-1 pol sequences
52. Lentiviral vectors Regulated gene expression
53. Efficient lentiviral transduction of liver requires cell cycling in vivo
54. Feline immunodeficiency virus vectors persistently transduce non-dividing airway epithelia and correct the cystic fibrosis defect
55. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo
56. Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector
57. Lentiviral-mediated gene transfer into human lymphocytes: Role of HIV-1 accessory proteins
58. Gene transfer into stimulated unstimulated T-lymphocytes by HIV-1-derived lentiviral vectors
59. Efficient gene transfer expression of biologically active glial cell line-derived neurotrophic factor in rat motoneurons transduced with lentiviral vectors
60. Bcl-x(L) protects adult septal cholinergic neurons from axotomized cell death
61. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer
62. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements In a 6-OHDA model of Parkinson's disease using GDNF
63. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin
64. Complete long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus
65. Therapeutic hemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
66. Gene-transfer tool: Herpes simplex virus vectors
67. Non-viral neuronal gene delivery mediated by the HC fragment of tetanus toxin
68. A powerful non-viral vector for in vivo gene transfer into the adult mammalian brain: Polyethylenimine
69. Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system
70. Mutation in the α-synuclein gene identified in families with Parkinson's disease
71. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
72. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
73. Acceleration of ollgomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis therapy
74. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
75. The ubiquitin pathway in Parkinson's disease
76. Low frequency of α-synuclein mutations in familial Parkinson's disease
77. A susceptibility locus for Parkinson's disease maps to chromosome 2p13
78. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments
79. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat
80. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacts of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
81. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
82. Subcellular localization of wild-type and Parkinson's disease-associated mutant a-synuclein in human and transgenic mouse brain
83. Dopaminergic loss and inclusion body formation in α-synuciein mice: Implications for neurodegenerative disorders
84. Neuropathology in mice expressing human α-synuclein
85. New animal models for Parkinson's disease
86. A Drosophila model of Parkinson's disease
87. Emerging treatments in Parkinson's disease
88. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
89. Several classes of new drugs emerging for Parkinson disease
90. Functional integration of neural grafts in Parkinson's disease
91. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
92. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease
93. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector
94. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors
95. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex
96. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease
97. Dopamine turnover and metabolism In the striatum of parkinsonian rats grafted with genetically-modified human astrocytes
98. Intrastriatal injection of an adenoviral vector expressing glial cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease
99. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease
100. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
101. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo
102. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
103. Translating cell biology Into therapeutic advances in Alzheimer's disease
104. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
105. Secreted amylold beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenllin 1 and 2 and APP mutations linked to familial Alzheimer's disease
106. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
107. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
108. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ- secretase activity
109. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
110. Evidence that tumor necrosis factor-α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor
111. Constitutive regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease
112. Transitionstate analogue inhibitors of γ-secretase bind directly to presenilin-1
113. Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells
114. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
115. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state
116. Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1
117. Role of forebrain cholinergic systems in learning and memory: Relevance to the cognitive deficits of aging Alzheimer's dementia
118. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
119. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
120. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
121. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
122. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo
123. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human Tau isoform
124. Neurodegenerative tauopathies: Human disease and transgenic mouse models
125. Prominent axonopathy in the brain spinal cord of transgenic mice overexpressing four-repeat human tau protein
126. Neuron loss in APP transgenic mice
127. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
128. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease
129. Skeletal CNS defects in presenilin-1-deficient mice
130. Presenilin 1 is required for Notch1 and Dli1 expression in the paraxial mesoderm
131. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
132. Ex vivo nerve growth factor gene transfer to the basal forebrain in presymptomatic middle-aged rats prevents the development of cholinergic neuron atrophy and cognitive impairment during aging
133. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy
134. Behavioral and anatomical deficits in mice homozygous for a modified β-amyloid precursor protein gene
135. β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity
136. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) α1 containing receptors and increases inferior collicular seizure sensitivity
137. Clinical trials of riluzoie in patients with ALS. ALS/Riluzole Study Group-II
138. Animal models of ALS
139. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
140. Amyotrophic lateral sclerosis structural defects in Cu/Zn superoxide dismutase
141. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation
142. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria
143. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of emyotrophic lateral sclerosis
144. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
145. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse
146. GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice
147. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors
148. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population
149. Prevention of motoneuron death by adenovirus-mediated neurotrophic factors
150. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis
151. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
152. Reporter gene expression for monitoring gene transfer
153. Repetitive non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals
154. Reversing neurodegeneration: A promise unfolds
155. Reversal of neuropathology motor dysfunction in a conditional model of Huntington's disease